Biological and Pharmaceutical Bulletin
The Pharmaceutical Society of Japan, established in 1880, is one of Japan’s oldest and most distinguished academic societies. The Society currently has around 18,000 members. It publishes three monthly scientific journals. Chemical and Pharmaceutical Bulletin (Chem. Pharm. Bull.) began publication in 1953 as Pharmaceutical Bulletin. It covers chemistry fields in the pharmaceutical and health sciences. Biological and Pharmaceutical Bulletin (Biol. Pharm. Bull.) began publication in 1978 as the Journal of Pharmacobio-Dynamics. It covers various biological topics in the pharmaceutical and health sciences. A fourth Society journal, the Journal of Health Science, was merged with Biol. Pharm. Bull. in 2012. Yakugaku Zasshi (Japanese for “Pharmaceutical Science Journal”) has the longest history, with publication beginning in 1881. Yakugaku Zasshi is published mostly in Japanese, except for some articles related to clinical pharmacy and pharmaceutical education, which are published in English.
The main aim of the Society’s journals is to advance the pharmaceutical sciences with research reports, information exchange, and high-quality discussion. The average review time for articles submitted to the journals is around one month for first decision. The complete texts of all of the Society’s journals can be freely accessed through J-STAGE. The Society’s editorial committee hopes that the content of its journals will be useful to your research, and also invites you to submit your own work to the journals.

Chairman of Committee
Ken-ichi Hosoya
Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama



Read more
9,471 registered articles
(updated on May 27, 2018)
Online ISSN : 1347-5215
Print ISSN : 0918-6158
1.683
2016 IMPACT FACTOR
JOURNALS PEER REVIEWED FREE ACCESS FULL-TEXT HTML ADVANCE PUBLICATION
Featured article
Volume 41 (2018) Issue 5 Pages 761-769
Protective Effect of Ipragliflozin on Pancreatic Islet Cells in Obese Type 2 Diabetic db/db Mice Read more
Editor’s picks

Ipragliflozin is a selective sodium glucose cotransporter 2 inhibitor that increases urinary glucose excretion, and subsequently improves glucolipotoxicity. The article by Takasu et al. demonstrated that the treatment with ipragliflozin decreased pancreatic cells positive for 4-hydroxy-2-nonenal (4HNE), an oxidative stress marker, in obese type 2 diabetes mellitus (DM) db/db mice. Histopathological examination of pancreatic islet cells revealed strong insulin staining, whereas reduced glucagon staining, accordingly pancreatic insulin content tended to be higher in the ipragliflozin 10 mg/kg-treated group compared with the DM-control group. It was demonstrated that ipragliflozin has a protective effect on the pancreas by reducing oxidative stress.

View the past featured articles
View all articles in Current issue
Most viewed articles Apr.2018
Share this page
Select past volume & issue
Journal news & Announcements
  • Biol. Pharm. Bull. Vol. 41 No. 3
    Current Topics: Cutting-Edge Studies Using Artificial Membranes
  • Biol. Pharm. Bull. Vol. 40 No. 12
    Current Topics: Recent Progress in the Study of Vasoactive Modulators in Metabolic and Cardiovascular Diseases



feedback
Top